Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity - PubMed (original) (raw)
. 2008 Apr 1;180(7):4606-14.
doi: 10.4049/jimmunol.180.7.4606.
Affiliations
- PMID: 18354183
- DOI: 10.4049/jimmunol.180.7.4606
Free article
Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity
Mercedes B Fuertes et al. J Immunol. 2008.
Free article
Abstract
Most tumors grow in immunocompetent hosts despite expressing NKG2D ligands (NKG2DLs) such as the MHC class I chain-related genes A and B (MICA/B). However, their participation in tumor cell evasion is still not completely understood. Here we demonstrate that several human melanomas (cell lines and freshly isolated metastases) do not express MICA on the cell surface but have intracellular deposits of this NKG2DL. Susceptibility to NK cell-mediated cytotoxicity correlated with the ratio of NKG2DLs to HLA class I molecules but not with the amounts of MICA on the cell surface of tumor cells. Transfection-mediated overexpression of MICA restored cell surface expression and resulted in an increased in vitro cytotoxicity and IFN-gamma secretion by human NK cells. In xenografted nude mice, these melanomas exhibited a delayed growth and extensive in vivo apoptosis. Retardation of tumor growth was due to NK cell-mediated antitumor activity against MICA-transfected tumors, given that this effect was not observed in NK cell-depleted mice. Also, mouse NK cells killed MICA-overexpressing melanomas in vitro. A mechanistic analysis revealed the retention of MICA in the endoplasmic reticulum, an effect that was associated with accumulation of endoH-sensitive (immature) forms of MICA, retrograde transport to the cytoplasm, and degradation by the proteasome. Our study identifies a novel strategy developed by melanoma cells to evade NK cell-mediated immune surveillance based on the intracellular sequestration of immature forms of MICA in the endoplasmic reticulum. Furthermore, this tumor immune escape strategy can be overcome by gene therapy approaches aimed at overexpressing MICA on tumor cells.
Similar articles
- Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A. Schwinn N, et al. Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098. Int J Cancer. 2009. PMID: 19089914 - Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Pende D, et al. Cancer Res. 2002 Nov 1;62(21):6178-86. Cancer Res. 2002. PMID: 12414645 - MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.
Menier C, Riteau B, Carosella ED, Rouas-Freiss N. Menier C, et al. Int J Cancer. 2002 Jul 1;100(1):63-70. doi: 10.1002/ijc.10460. Int J Cancer. 2002. PMID: 12115588 - Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB, Domaica CI, Zwirner NW. Fuertes MB, et al. Front Immunol. 2021 Jul 29;12:713158. doi: 10.3389/fimmu.2021.713158. eCollection 2021. Front Immunol. 2021. PMID: 34394116 Free PMC article. Review. - Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E, Vassena L, Cerboni C, Doria M. Giuliani E, et al. Curr Drug Targets. 2016;17(1):54-64. doi: 10.2174/1389450116666150630110329. Curr Drug Targets. 2016. PMID: 26122035 Review.
Cited by
- Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S. Lu X, et al. Cancer Sci. 2010 Mar;101(3):609-15. doi: 10.1111/j.1349-7006.2009.01439.x. Epub 2009 Nov 16. Cancer Sci. 2010. PMID: 20028385 Free PMC article. - Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Bae JH, Kim SJ, Kim MJ, Oh SO, Chung JS, Kim SH, Kang CD. Bae JH, et al. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15. Cancer Sci. 2012. PMID: 21951556 Free PMC article. - Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
Son CH, Keum JH, Yang K, Nam J, Kim MJ, Kim SH, Kang CD, Oh SO, Kim CD, Park YS, Bae J. Son CH, et al. Radiat Oncol. 2014 Feb 10;9:49. doi: 10.1186/1748-717X-9-49. Radiat Oncol. 2014. PMID: 24512718 Free PMC article. - Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E, McLeish E, Blancafort P, Coudert JD, Gaudieri S. Alves E, et al. Front Immunol. 2021 Aug 12;12:712722. doi: 10.3389/fimmu.2021.712722. eCollection 2021. Front Immunol. 2021. PMID: 34456921 Free PMC article. - CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells.
Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang YH, Kuo TT, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS. Chen Z, et al. J Exp Med. 2011 Dec 19;208(13):2633-40. doi: 10.1084/jem.20102575. Epub 2011 Dec 5. J Exp Med. 2011. PMID: 22143889 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials